APA引文

Vermeire, S., Lukáš, M., Magro, F., Adsul, S., Lindner, D., Rosario, M., . . . Danese, S. (2020). Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis. J Crohns Colitis.

Citação norma Chicago

Vermeire, Séverine, Milan Lukáš, Fernando Magro, Shashi Adsul, Dirk Lindner, Maria Rosario, Jeannine Roth, and Silvio Danese. "Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis." J Crohns Colitis 2020.

MLA引文

Vermeire, Séverine, et al. "Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis." J Crohns Colitis 2020.